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Background. Genetic variants in the nuclear transcription receptor, PPARG, are associated with cardiometabolic traits, but reports
remain conflicting. We determined the frequency and the clinical relevance of PPARG SNPs in an African mixed ancestry
population.Methods. In a cross-sectional study, 820 participants were genotyped for rs1800571, rs72551362, rs72551363, rs72551364,
and rs3856806, using allele-specific TaqMan technology. The homeostatic model assessment of insulin (HOMA-IR), 𝛽-cells
function (HOMA-B%), fasting insulin resistance index (FIRI), and the quantitative insulin-sensitivity check index (QUICKI) were
calculated. Results. No sequence variants were found except for the rs3856806.The frequency of the PPARG-His447His variant was
23.8% in the overall population group, with no difference by diabetes status (𝑃 = 0.215). The His447His allele T was associated
with none of the markers of insulin resistance overall and by diabetes status. In models adjusted for 2-hour insulin, the T allele was
associated with lower prevalent diabetes risk (odds ratio 0.56 (95% CI 0.31–0.95)). Conclusion. Our study confirms the almost zero
occurrences of known rare PPARG SNPs and has shown for the first time in an African population that one of the common SNPs,
His447His, may be protective against type 2 diabetes.
1. Introduction
Peroxisome proliferator-activated receptor gamma (PPARG)
is one of the three PPARs isotypes; the other two are PPAR𝛼
and PPAR𝛽/𝛿. The PPARG is mainly expressed in adipose
tissue whilst PPAR𝛼 is expressed mostly in brown adipose
tissue and liver, and PPAR𝛽/𝛿, which is found in many
tissues, is mostly expressed in gut, kidney, and heart [1, 2].
Expression of PPARs occurs when heterodimers are formed
with the retinoid X receptor (RXR) and binds to specific
PPAR responsive elements of DNA to promote transcription.
The PPAR: RXR complex is activated via ligand binding
to PPARs resulting in the release of corepressors bound
to the receptor and recruitment of coactivators to initiate
transcription of target genes [3–5]. For example, antidiabetic
drugs of the thiazolidinedione family are believed to target
the transcription factor PPARG to improve insulin sensitivity
in type 2 diabetes (T2D) and induce glucose transporter 4
mRNA expression in fat and muscle [6–8].
Naturally occurring PPARG polymorphisms have been
described in several studies. The two common variants
of the PPARG gene, Pro12Ala and His447His, have been
associated with metabolic states of obesity, insulin resis-
tance, type 2 diabetes, and metabolic syndrome [9]. The
His447His polymorphism (also referred to as C161T, C1431T,
or CAC478CAT, His449His) is a silent mutation at exon 6
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and is considered a better predictor of fasting insulin levels
and insulin resistance than Pro12Ala [10]. In our previous
analysis, the presence of PPARG Pro12 conferred a 64%
higher risk of prevalent type 2 diabetes, but we failed to
demonstrate an associationwithmarkers of insulin resistance
[11]. In the present study, we therefore investigated the
association between cardiometabolic traits, His447His, and
other PPARG polymorphisms.
2. Materials and Methods
2.1. Baseline Evaluations. This investigation is based on
the Bellville South cohort from Cape Town, South Africa,
which has received study approval from the Research Ethics
Committees of the University of Stellenbosch (HREC refer-
ence number N09/05/146) and Cape Peninsula University of
Technology Faculty of Health and Wellness Sciences Ethics
Committee (reference numbers CPUT/HW-REC 2008/002
andCPUT/HW-REC2010).The studywas conducted accord-
ing to the code of ethics of the World Medical Association
(Declaration of Helsinki). A detailed description of the
research setting has been previously described [12, 13]. Briefly,
Bellville South is predominantly a mixed ancestry township
located in the northern suburb of Cape Town in the Tyger-
berg subdistrict. The mixed ancestry, commonly referred
to as coloured, is a South African population group with
32–43% Khoisan, 20–36% Bantu-speaking African, 21–28%
European, and 9–11% Asian ancestry [14]. All participants
received a standardized interview and physical examination
during which blood pressure was measured according to the
World Health Organisation (WHO) guidelines [15] using a
semiautomated digital blood pressure monitor (Rossmax PA,
USA) on the right arm in a sitting position. Anthropometric
measurements were performed three times and their average
was used for analysis: weight (kg), height (cm), waist (cm),
and hip (cm) circumferences. Participants with no history
of doctor-diagnosed diabetes mellitus underwent a 75 g oral
glucose tolerance test (OGTT) as recommended by the
WHO [16]. Further, the following biochemical parameters
were determined on the Cobas 6000 Clinical Chemistry
instrument (Roche Diagnostics, Germany): fasting plasma
glucose, insulin, creatinine, total cholesterol (TC), high den-
sity lipoprotein cholesterol (HDL-c), triglycerides (TG), C-
reactive protein (CRP), 𝛾-glutamyltransferase (GGT), and
glycated haemoglobin (HbA1c) certified by the National
Glycohemoglobin Standardisation Programme (NGSP). Low
density lipoprotein cholesterol (LDL-c) was calculated using
Friedewald’s formula [17].
2.2. SNP Genotyping. Genomic DNA was extracted from
whole blood samples collected in an EDTA tube. Sin-
gle nucleotide polymorphisms (SNPs) in the PPARG,
Pro115Gln (rs1800571, G>T), Val290Met (rs72551362, G>A),
Pheu388Leu (rs72551363, T>A), Arg397Cys (rs72551364,
C>T), and His447His (rs3856806, C>T), were genotyped
using high throughput real-time polymerase chain reaction
(RT-PCR) in two independent laboratories on the ABI Prism
7900HT platform (Applied Biosystems, USA) and a Bio-
Rad Optica (BioRad, USA) using TaqMan genotyping assay
(Applied Biosystems, USA). Conventional polymerase chain
reaction followed by direct DNA sequencing was performed
for analytical validation of high throughput genotyping.
2.3. Definitions and Calculations. Body mass index (BMI)
was calculated as weight per square meter (kg/m2) and waist-
hip-ratio (WHR) as waist/hip circumferences (cm). Type 2
diabetes status was based on a history of doctor-diagnosis, a
fasting plasma glucose ≥7.0mmol/L, and/or a 2-hour post-
OGTT plasma glucose ≥11.1mmol/L.The homeostatic model
assessment of insulin resistance (HOMA-IR) was calculated
according to the formula HOMA-IR = fasting insulin con-
centration (mIU/L) × fasting plasma glucose (mmol/L)/22.5,
while functional 𝛽-cells (HOMA-B%) were estimated using
the formula 20 × fasting insulin (𝜇IU/mL)/fasting glucose
(mmol/mL) − 3.5. The fasting insulin resistance index (FIRI)
was calculated with the formula (fasting insulin (𝜇U/mL) ×
fasting glucose (mM))/25 and the quantitative insulin-
sensitivity check index (QUICKI) was calculated as 1/log
fasting insulin (𝜇U/mL) × log (fasting glucose (mg/dL)).
Glomerular filtration rate (GFR) was estimated by the 4-
variable modification of diet in renal disease (MDRD) equa-
tion [18, 19] applicable to standardised serum creatinine
values.
2.4. Statistical Analysis. Of the 946 participants who took
part in the survey, 941 consented for genetic studies. Among
the latter, 121 were excluded for missing data on the genetic
variables. Therefore, 820 had valid data for the current
analyses. General characteristics of the study group are
summarized as count and percentage for dichotomous traits,
mean and standard deviation (SD), or median and 25th–75th
percentiles for quantitative traits. Traitswere log-transformed
to approximate normality, where necessary, prior to analy-
sis. SNPs were tested for departure from Hardy-Weinberg
equilibrium (HWE) expectation via a chi-square goodness of
fit test. Linear regression models were used for the analysis
of quantitative traits and logistic regression models for
dichotomous traits, always assuming additive models for the
SNPs. Using linear and logistic models enabled us to adjust
all analyses for known confounders as specified everywhere
in the results. We investigated the additive allelic association
of each SNP with each trait, overall and according to type
2 diabetes status, and tested for heterogeneity by adding
the interaction term of type 2 diabetes and each SNP to
a model that contained the main effects of type 2 diabetes
and the relevant SNP. Results corresponding to 𝑃 values
below 5% are described as significant. We did not adjust for
multiple testing. All analyses used the statistical package R
(version 3.0.0 (2013-04-03), The R Foundation for Statistical
Computing, Vienna, Austria).
3. Results
Clinical characteristics of participants overall and according
to diabetes status are summarized in Table 1 indicating that
222 (27%) participants had type 2 diabetes. As expected,
the distribution of the level of insulin resistance/sensitivity
indicators was significantly different between the two groups
International Journal of Endocrinology 3
Table 1: General characteristics of the overall population and by diabetic status.
Variable No diabetes Diabetes 𝑃-value Overall
Number 598 222 820
Gender, male 𝑛 (%) 130 (21.7) 48 (21.6) 0.9474 178 (21.7)
Mean age, year (SD) 51.0 (15.1) 58.9 (13.4) <0.0001 53.2 (15.1)
Mean systolic blood pressure, mmHg (SD) 122 (19) 130 (23) <0.0001 124 (21)
Mean diastolic blood pressure, mmHg (SD) 75 (12) 77 (14) 0.0506 76 (13)
Hypertension, 𝑛 (%) 314 (52.5) 133 (59.9) 0.05859 447 (54.5)
Mean body mass index, kg/m2 (SD) 29.2 (7.0) 31.8 (7.1) <0.0001 29.9 (7.1)
Mean waist circumference, cm (SD) 95 (15) 102 (14) <0.0001 97 (15)
Mean hip circumference, cm (SD) 109 (14) 112 (15) 0.014 109 (14)
Mean waist/hip ratio, (SD) 0.87 (0.10) 0.91 (0.10) <0.0001 0.88 (0.09)
Mean HbA1c, % (SD) 5.7 (0.4) 7.8 (2.1) <0.0001 6.3 (1.4)
Mean fasting blood glucose, mmol/L (SD) 5.1 (0.7) 9.8 (4.5) <0.0001 6.4 (3.2)
Mean 2 h glucose, mmol/L (SD) 6.4 (1.6) 13.4 (5.3) <0.0001 7.5 (3.6)
Mean eGFR, mL/min (SD) 76.2 (21.2) 72.0 (25.2) 0.029 75.0 (22.4)
Mean triglycerides, mmol/L (SD) 1.4 (0.9) 1.7 (0.9) <0.0001 1.5 (0.9)
Mean HDL cholesterol, mmol/L (SD) 1.3 (0.4) 1.2 (0.3) 0.0002 1.3 (0.4)
Mean LDL cholesterol, mmol/L (SD) 3.6 (1.0) 3.7 (1.1) 0.179 3.6 (1.0)
Mean total cholesterol, mmol/L (SD) 5.5 (1.2) 5.7 (1.3) 0.068 5.6 (1.2)
Median GGT (25th–75th percentiles) 26 [17–39] 32 [23–49] <0.0001 27 [19–42]
Median CRP (25th–75th percentiles) 3.3 [0.9–8.3] 5.4 [2.2–10.9] <0.0001 4.0 [1.2–9.4]
Median insulin mmol/L (25th–75th percentiles) 7.2 [3.4–12.9] 10.2 [4.4–17.6] 0.0001 7.7 [3.5–14.1]
Median 2 h insulin mmol/L (25th–75th percentiles) 36.0 [19.3–65.7] 53.3 [22.1–117.0] 0.0015 37.3 [19.5–72.7]
Median glucose/insulin (25th–75th percentiles) 0.71 [0.40–1.45] 0.82 [0.48–2.05] 0.0304 0.72 [0.41–1.58]
Median HOMA-IR (25th–75th percentiles) 1.63 [0.69–3.00] 3.67 [1.71–7.29] <0.0001 1.94 [0.86–3.82]
Median HOMA-B% (25th–75th percentiles) 92.8 [43.5–165.1] 42.1 [13.6–83.4] <0.0001 74.2 [32.2–149.2]
Median QUICKI (25th–75th percentiles) 0.15 [0.14–0.18] 0.14 [0.12–0.15] <0.0001 0.15 [0.14–0.17]
Median FIRI (25th–75th percentiles) 1.46 [0.62–2.70] 3.31 [1.54–6.56] <0.0001 1.74 [0.77–3.44]
Median 1/HOMA-IR (25th–75th percentiles) 0.61 [0.33–1.44] 0.27 [0.14–0.58] <0.0001 0.52 [0.26–1.16]
CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; FIRI: fasting insulin-resistance index; GGT: 𝛾-glutamyltransferase; HbA1c: glycated
haemoglobin;HDL: high density lipoproteins;HOMA-B%: functional𝛽-cells;HOMA-IR: homeostaticmodel assessment of insulin resistance; LDL: lowdensity
lipoproteins; QUICKI: the quantitative insulin-sensitivity check index; SD: standard deviation.
all 𝑃 < 0.0001, except for glucose/insulin ratio (𝑃 = 0.0304).
Furthermore, compared with nondiabetic participants, those
with diabetes were significantly older (58.9 versus 51.0 years,
𝑃 < 0.0001) and had higher levels of adipometric variables
(all 𝑃 ≤ 0.014), systolic blood pressure (𝑃 < 0.0001),
triglycerides (𝑃 < 0.0001), GGT, and CRP (both 𝑃 < 0.0001),
whilst eGFR (𝑃 = 0.029) and HDL cholesterol (𝑃 = 0.0002)
were significantly lower.
No mutations were found for the following SNPs
of PPARG: Pro115Gln, Val290Met, Pheu388Leu, and
Arg397Cys. The PPARG, His447His, variant was in HWE
(𝑃 > 0.05) and its genotype and allele distribution overall and
by diabetes status are summarized in Table 2. The frequency
of the PPARG (rs3856806), C/T genotype, was 23.8% in the
overall population group and the genotype distributions did
not differ significantly between the nondiabetic and diabetic
groups. Overall, the T allele frequency was 14%; however,
although not significant (𝑃 = 0.128), the T allele did occur
more in the nondiabetic (14.8%) than in the diabetic (11.7%)
participants.
In generalized linear regression analyses adjusted for age,
sex and diabetes (Table 3), PPARG His447His allele T was
associated with none of the markers of insulin resistance
overall and by diabetes status. There was a borderline sta-
tistical interaction in the effect by diabetes status for the
association with fasting glucose (interaction 𝑃 = 0.092),
HOMA-IR and FIRI indices (both 𝑃 = 0.076). Further-
more, the effects always appeared to be sizable and negative
(although nonsignificant) among the diabetic and almost null
in nondiabetic participants.
In the logistic regression models (Table 4) PPARG allele
T was associated with odds ratio of 0.76 (95% confidence
interval 0.55–1.05) for prevalent diabetes.The effect estimates
broadly remained within the same range after adjustment for
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Table 2:Genotype distributions,minor allele frequencies, andunadjusted𝑃-values for comparing genotype distribution according to diabetes
status and additive allelic effects between diabetes groups.
No diabetes Diabetes 𝑃-value Overall
𝑁 598 222 820
PPARG (rs3856806)
C/C, 𝑛 (%) 436 (72.9) 172 (77.5) 0.215 608 (74.1)
C/T, 𝑛 (%) 147 (24.5) 48 (21.6) 195 (23.8)
T/T, 𝑛 (%) 15 (2.5) 2 (0.9) 17 (2.1)
T, 𝑛 (%) 177 (14.8) 52 (11.7) 0.128 229 (14.0)
HWE (𝑃-value) 0.517 0.747 0.771
HWE: Hardy-Weinberg equilibrium (HWE 𝑃-values are from exact tests); PPARG: peroxisome proliferator-activated receptor gamma.
age and sex, with or without further adjustment for various
indices of insulin resistance/sensitivity. However, in model
containing sex, age, and 2-hour insulin, PPARG allele T was
significantly associated with a lower prevalent diabetes risk
with an odds ratio of 0.56 (95% CI: 0.31–0.95).
4. Discussion
The present study reports five PPARG SNPs, rs1800571,
rs72551362, rs72551363, rs72551364, and rs3856806. Only
His447His (rs3856806) was found to be polymorphic and
demonstrated an association with diabetes risk. The T allele
frequencies were about 14% and, in an additive geneticmodel,
we observed that the presence of the T allele significantly
reduced the risk of diabetes by 44%. Furthermore, the T
allele was associatedwith reduced fasting blood glucose levels
and HOMA-IR and FIRI indices. However these associations
were borderline and did not reach statistical significance.
The nuclear transcription receptor, PPARG, acts as a
regulator of adipocyte differentiation, pancreatic beta cell
function, and lipid and glucose metabolism [20–22]. Despite
its biological plausibility, previously reported association
studies with obesity [23–25], insulin resistance [10, 25], type 2
diabetes [11, 26], andmetabolic syndrome [27] are conflicting.
For instance, some studies have reported that carriers of the
T allele of His447His (rs3856806) have increased obesity
risk [23], poor lipid profile [28–30], and risk of metabolic
syndrome [27] and coronary heart diseases (CHD) [9].
On the other hand, others have failed to demonstrate an
association between PPARG SNPs including C161T with
CHD susceptibility [31], whilst some have shown increased
insulin sensitivity [10, 26], decreased CHD, body mass index,
and diabetes risk [25, 26, 29, 32] in subjects harbouring the
T allele. In our study, presence of the T allele was associated
with reducing the risk of prevalent diabetes and levels of
insulin resistance indices. Aspects that may contribute to the
inconsistencies in these studies include variations in ethnic
distribution of PPARG polymorphisms, the statistical power
of the studies, environmental-gene and gene-gene factors,
and different levels of adjustment for potential confounding
factors across studies. For example, in our study, the T allele
frequency of the His447His variant (14%) was similar to that
reported in the Australian Caucasians, 16.3% [2], and the
Tunisians, 18.3% [27], whilst in the Chinese a frequency of
29.2% has been reported [33]. Furthermore, two recent stud-
ies have shown that gene-gene interaction analysis is superior
to single PPARG polymorphisms for the quantification of
effects with cardiometabolic traits [33, 34]. For example,
Luo et al. [33] investigated the association of 10 PPARG SNPs
with obesity and found that only two SNPs, rs2016520 and
rs10865170, were associated with lower obesity risk. However,
in generalized multifactor dimensionality reduction analysis
to assess the effect of interaction among the 10 SNPs, an
additional SNP, rs9794, was identified and showed a potential
gene-gene interaction with rs2016520 and rs10865170 [33].
We also genotyped some of the PPARG SNPs, rs1800571,
rs72551362, rs72551363, and rs72551364, but no genetic vari-
ations were observed. The rs1800571, Pro115Gln, gain-of-
function mutation has only been found in five German
morbid obese subjects since its initial identification by
Ristow et al. [35], where three of the four obese subjects
with the genetic variant also had type 2 diabetes. In another
German population study, another carrier of the mutant
with severe insulin resistance was identified [36]. However,
other studies involving German, Danish, and American
populations failed to find this mutation [37–40]. Similarly,
there has not been more than one individual in which either
rs72551362, rs72551363, or rs72551364 has been found [41–
43].The rare nature of these mutations suggests that standard
population-based type studies are likely not the suitable
design to investigate them, considering the requirements for
very large sample size. Rather, targeting specific segments
of the population such as people with morbid obesity for
screening may increase the likelihood of uncovering some
with themutation. It is also possible thatmutations other than
those reported so far could be present in other populations,
indicating the need for genome-wide scanning studies in
different setting to capture additional mutations.
Our study has some limitations and these include the
investigation of only five SNPs and small sample size. How-
ever, the participants in this studywerewell characterised and
we used both fasting and oral glucose tolerance test derived
indices for the assessment of type 2 diabetes and insulin
resistance. In conclusion, our study confirmed the almost
zero occurrences of known rare PPARG SNPs and has shown
that one of the common SNPs, His447His, may be protective
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Table 4: Odds ratio and 95% confidence intervals from logistic regression for the prediction of diabetes.
Allele Covariates OR (95% CI) 𝑃
PPARG (rs3856806)T
None 0.76 (0.55 to 1.06) 0.112
sex, age 0.74 (0.53 to 1.03) 0.082
sex, age, insulin 0.75 (0.53 to 1.05) 0.098
sex, age, 2 h insulin 0.56 (0.31 to 0.95) 0.042
sex, age, HOMA-IR 0.77 (0.53 to 1.10) 0.157
sex, age, QUICKI 0.75 (0.53 to 1.04) 0.094
sex, age, FIRI 0.77 (0.53 to 1.10) 0.157
sex, age, glucose/insulin 0.75 (0.53 to 1.04) 0.092
FIRI: fasting insulin resistance index; HOMA-IR: homeostatic model assessment of insulin resistance; PPARG: peroxisome proliferator-activated receptor;
QUICKI: the quantitative insulin-sensitivity check index.
against type 2 diabetes. Future larger studies with more SNPs
involving populations from Africa need further exploration.
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